Gemfibrozil capsules (Gemfibrozil Capsules), the contents of the product as a white powder. This product contains gemfibrozil (C15H22O3) 90.0% of the labeled amount of 110.0%. Sealed and kept in a cool dry place. For hyperlipidemia. Apply to serious type Ⅳ or Ⅴ hyperlipoproteinemia, and coronary heart disease risk of large and diet control, reduce weight and other treatment fails. Formulations/specifications 0.3g. Category with gefitinib Luo Qi. Production enterprises Tianjin Golden World Pharmaceutical Co. Taiyuan World Yue Pharmaceutical Co., Ltd., Shanghai Baolong Pharmaceutical Co., Ltd..
drug nameCommon name: gefitinib Luo Qi Capsules
trade name: Yue Heng
English name: Gemfibrozil Capsules
Hanyu Pinyin: Jifeiluoqi Jiaonang
gefitinib Luo Qi Structure
Its structural formula is:
Molecular formula: C15H22O3
Molecular weight: 250.34
Physical and Chemical Propertiescrystallization from hexane, the melting point of 61-63 ° C, the boiling point of 1158 to 159 ° C/2.67Pa.
synthesis methodgenerated by the 2,5 - dimethyl phenol and bromochloropropane of reaction of 1 - (2,5 - dimethyl phenoxy) -3 - chloropropane . The reaction in toluene, adding a new clean and destroy refluxed for 5h. 2 the same thing by isobutyl sodium and different amine lithium reaction to generate lithium on behalf of the isobutyric acid. (3) 1 - (2,5 - dimethylphenoxy) -3 - chloro-propane and lithium on behalf of the isobutyric acid synthetic phenoxy valerate. These two intermediates in the 10-15 ℃ slowly mixing, stirring 15min. And then heated to 30 ° C, insulation response 5h.
pharmacology and toxicologyThis product clofibrate acid derivative class of lipid regulating drugs, the mechanism of lipid-lowering effect has not yet fully understood, may involve the peripheral lipolysis, reduce the liver uptake and intrahepatic triglyceride reduction in free fatty acid formation, inhibition of very low density lipoprotein apolipoprotein synthesis to reduce the generation of very low density lipoprotein. This product is to lower blood triglycerides increased blood concentration of high density lipoprotein, can slightly lower blood LDL cholesterol blood concentration, hyperlipoproteinemia type Ⅳ may make low-density lipoprotein has been increased. 5-year placebo-controlled studies have shown that this product can reduce the severe sudden coronary death, myocardial infarction.
10 times the human dose of long-term to rats, liver cancer and benign testicular tumor incidence increase.
pharmacokineticsThis product is absorbed from the gastrointestinal tract completely, the peak plasma concentration 1-2 hours after oral administration; T1/2 of 1.5 hours, plasma protein binding rate about 98%. Hypolipidemic effect began to appear 2-5 days after treatment, the peak role appeared at 4 weeks. Metabolized in the liver, about 70 percent of drug excreted by the kidneys, the prototype. 6% from the feces.
indications for hyperlipidemia. Apply to serious type Ⅳ or Ⅴ hyperlipoproteinemia, and coronary heart disease risk of large and diet control, reduce weight and other treatment fails. Also apply in the type Ⅱ b hyperlipoproteinemia, and coronary heart disease risk of large and diet control, weight loss, and other lipid regulating drug therapy. In view of the potential carcinogenic effects on human risk and should be used strictly limited within the specified range of indications, and the effect was not obvious should be promptly discontinued.
GMT+8, 2015-7-3 07:26 , Processed in 0.036879 second(s), 3 queries , Gzip On, Memcache On.